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Neuroendocrine tumors are a heterogeneous group of malignancies that present a diagnostic challenge. Themajority
of patients (more than 60%) present with metastatic disease at diagnosis. The diagnosis is based on histopathology,
imaging, and circulating biomarkers. The histopathology should contain specific neuroendocrine markers such as
chromogranin A, synaptophysin, and neuron-specific enolase and also an estimate of the proliferation by Ki-67 (MIB-
1). Standard imaging procedures consist of computed tomography or magnetic resonance imaging together with
somatostatin receptor scintigraphy. 68Ga-DOTA-octreotate scans will in the future replace somatostatin receptor
scintigraphy because they have higher specificity and sensitivity. Other positron imaging tomographic scanning
tracers that will come into clinical use are 18F-DOPA and 11C-5HTP. Neuroendocrine tumors secrete many different
peptides and amines that can be used as circulating biomarkers. The most useful general marker is chromogranin A,
which is both a diagnostic and prognostic marker in most neuroendocrine tumors. However, there is still a need for
improved biomarkers for early detection and follow-up of patients during treatment. In addition, molecular imaging
can be further developed for both detection and evaluation of treatment.
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INTRODUCTION
Neuroendocrine tumors (NETs) comprise a heteroge-
neous group of neoplasms that are frequently metastatic at
the time of diagnosis, and distance of metastatic disease is,
next to grading, one of the most important prognostic
factors (1–3). The availability of modern imaging methods
for diagnosis and staging of NETs has improved at the same
time as the spectrum of therapeutic options in the manage-
ment of metastatic disease has increased during recent
years. The frequency of metastatic disease varies depending
on the type of tumor, but in specialized centres, 80–90% of
patients who present with small intestinal NETs (carcinoids)
and 60–70% of patients with pancreatic NETs have liver
metastases. Histology is the strongest predictor of survival.
In the most recent SEER (Surveillance Epidemiology and
End Results) database analyses, median survival in distant
metastatic disease was 33 months in patients with G1/G2
NETs and only 5 months in patients with poorly differ-
entiated tumors (neuroendocrine carcinoma (NEC) G3) (1).
In specialized centres for the treatment of NETs, overall 5-
year survival rates for patients with stage IV, pancreatic and
small intestinal NETs are much higher than those reported
in the SEER database (3). In such centres, 5-year survival rates
in patients with metastatic midgut NETs exceed 50% (4,5). In
a multivariate analysis of patients with well-differentiated
tumors and moderately differentiated NETs from the SEER
database, disease stage, primary tumor site, histologic grade,
sex, race, age and year at diagnosis were predictors of
outcome (p,0.001). In my centre, in a multivariate analysis
of 354 patients with pancreatic NETs, the prognostic
factors were TNM stage, World Health Organization
(WHO) classification, Ki67, and radical surgery (6). Liver
tumor burden, or number of metastases, tumor slope,
extrahepatic disease, co-morbidities and performance status
represent additional prognostic parameters (3,7). Retro-
spective data indicate that circulating chromogranin A
(CgA) is of prognostic value; highly elevated levels were
associated with limited survival (8,9). Other prognostic
markers that are available (e.g., CK19, PTEN, TSC-2 expres-
sion in tumor tissue) require further validation (10,11).
DIAGNOSTIC WORK-UP
The initial diagnostic approach in patients with NETs
includes histological examination, which is always required
before therapeutic decisions are made. Clinicians should
also consider performing repetitive biopsies to reassess the
prognosis if the disease course changes significantly. The
following investigations are also required: (a) immunohis-
tochemical markers and detailed histological analysis;
(b) assessment of the primary tumor and the extent of
extrahepatic spread by imaging, including patterns of
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hepatic metastases; and (c) biochemical assessment of
functionality and general tumor markers.
HISTOPATHOLOGY
The neuroendocrine signature of a cell is defined by the
expression of general and specific neuroendocrine markers.
General neuroendocrine markers are observed in all cell
types, and include the cytosol antigens neuron-specific
enolase (NSE) and protein gene product 9.5 (PGP 9.5), as
well as the secretory vesicle antigens of chromogranin family
A for large dense core vesicle (LDCV) and synaptophysin for
small synaptic vesicles (SSV). Other neuroendocrine tissue
markers are the ATP-dependent vesicular monoamine
transporter isoforms (VMAT1 and VMAT2), neuroendocrine
secretory protein 55 (NESP55), synaptic vesicle protein 2
(SV2) in both LDCVs and SSV, and neural cell adhesion
molecule (N-CAM) (12,13).
Immunohistochemical determination of CgA and synapto-
physin as well as proliferation marker Ki-67 (MIB-1) is
mandatory. In patients with multiple endocrine neoplasia
type 1, specific markers such as gastrin, insulin, and pancreatic
polypeptide (PP) should be determined. For patients with
unknown primary tumors, TTF1 (bronchial/lung), CDX2
(intestinal serotonin-midgut), and PP/Islet-1/Glucagon (pan-
creatic) can be used to guide the search for the primary tumor
(14,15).
CLASSIFICATION
The current WHO 2010 classification introduces the
definition ‘‘neoplasm’’ to encompass low- to high-grade
neuroendocrine tumors (16). At variance with theWHO 2000
classification, the neuroendocrine connotation is enforced, in
recognition of the expression of antigens shared with nerve
elements. The classification itself uses a common definition
frame that is based on grading and specific staging tools. The
definitions are NET for the previous ‘‘carcinoid’’/well-
differentiated endocrine tumor/carcinoma, and neuroendo-
crine carcinoma (NEC) for the previous small cell/poorly
differentiated carcinoma.
TUMOR STAGING AND GRADING
Staging is performed with the familiar tumor node
metastasis (TNM) approach according to the anatomical
location of the tumors, and this approach is recommended by
the WHO, the American Joint Committee on Cancer and the
International Union Against Cancer. However, at variance
with the European Neuroendocrine Tumor Society proposal,
the WHO-approved TNM staging system is conceived for
‘‘carcinoid’’ only, and some parameters for the appendix and
the pancreas are different (see Table 1) (17–20).
Grading is performed by definition of proliferation using
both the mitotic count and the Ki-67 index, as proposed by
the European Neuroendocrine Tumor Society. Notably, both
the WHO and the American Joint Committee on Cancer
endorse such a grading system.
IMAGING
A standard computed tomographic (CT) scan of the chest,
abdomen, and pelvis or magnetic resonance image is
mandatory, and should be complemented by somatostatin
receptor scintigraphy including single photon emission
computer tomography (SPECT)-SRS and triphasic CT
(21,22). Positron emission tomographic (PET) scanning
using 68Ga-somatostatin analogue (68Ga-DOTATOC-PET/
CT) is an alternative if available, as it has higher resolu-
tion than additional somatostatin receptor scintigraphy.
Table 1 - The American Joint Committee on Cancer (AJCC) and European Neuroendocrine Tumors Society (ENETS)
staging classifications for pancreatic neuroendocrine tumors with cross-tabulation of stage distributions.
AJCC Staging Classification ENETS Staging Classification
T1 Tumor limited to the pancreas,
,2 cm
T1 Tumor limited to the pancreas,
,2 cm
T2 Tumor limited to the pancreas,
.2 cm
T2 Tumor limited to the pancreas,
2-4 cm
T3 Tumor extends beyond the pancreas, but not involving the celiac
axis or SMA
T3 Tumor limited to the pancreas,
.4 cm, or invading duodenum or CBD
T4 Tumor involves the celiac axis or SMA T4 Tumor invades adjacent structures
N0 No regional LN metastasis N0 No regional LN metastasis
N1 Regional LN metastasis N1 Regional LN metastasis
M0 No distant metastasis M0 No distant metastasis
M1 Distant metastasis M1 Distant metastasis
Stage T N M Stage T N M
IA T1 N0 M0 I T1 N0 M0
IB T2 N0 M0 IIA T2 N0 M0
IIA T3 N0 M0 IIB T3 N0 M0
IIB T1-3 N1 M0 IIIA T4 N0 M0
III T4 N0-1 M0 IIIB Any T N1 M0
IV Any T Any N M1 IV Any T Any N M1
ENETS I ENETS II ENETS III ENETS IV
AJCC I 25 59 0 0
AJCC II 0 4 37 0
AJCC III 0 0 18 0
AJCC IV 0 0 0 282





68Ga-DOTATOC-PET/CT may help to identify the primary
tumor, and is a reliable method for early detection of bone
metastases in patients with NETs (23–25). For the detection
of small pancreatic NETs, endoscopical ultrasonography
seems superior to PET/CT (26). In general, PET should be
replaced by PET/CT; 18F-DOPA PET/CT and 5-HTP-PET/
CT are promising diagnostic tools, and may be considered if
they are available and if somatostatin receptor imaging is
negative (27,28). However, their use in the standard work-
up may not be recommended at this time. Although recent
studies indicate a prognostic value of FDG-PET in well-
differentiated NETs, it is not recommended as a routine
imaging method (29). Further studies are needed to support
its role as a prognostic tool. In special situations, for
example if liver transplantation is being considered, FDG-
PET/CT can be considered for G2 tumors as well as 18F-
DOPA-PET/CT or 5HTP-PET/CT if available. Investigation
of the large bowel may be useful, either by means of a
colonoscopy plus ileoscopy, or by means of a colon CT with
a neutral enema. In a retrospective analysis of 123 patients
with NET liver metastases of unknown primary, in 47% the
primary tumor was localized in the small or large intestine
by lower endoscopy (30). If the primary tumor is suspected
to be in the small intestine, double balloon enteroscopy or
video capsule endoscopy may be performed if available and
considered necessary for the therapeutic management. If the
CT study of liver metastases is inconclusive, T2-weighted
thin-slice dynamic gadolinium-enhanced magnetic reso-
nance imaging, or, if available, contrast-enhanced ultra-
sonography, should be performed. Magnetic resonance
imaging is considered superior to CT in the detection and
follow-up of liver metastases, and is a preferable choice in
clinical trials (21).
The imaging report should include segmental information
on the distribution of liver metastases. Although there are
no standardized imaging techniques to reliably measure
liver tumor burden, an experienced radiologist can use such
reports to estimate the percentage of liver tumor involved.
CIRCULATING MARKERS IN CLINICAL PRACTICE
The minimal biochemical work-up for NETs includes
circulating chromogranin A and assessment of a specific
marker to assess functionality, such as urinary 5-HIAA
evaluation in carcinoid syndrome. Additional assessment of
insulin, C-peptide, (proinsulin), gastrin, pancreatic poly-
peptide, vasoactive intestinal peptide, glucagon, and calci-
tonin should be useful, depending on the functional status
of the tumor, clinical symptoms, and histological features.
Chromogranins are a family of glycoproteins found in
many hormone-producing organs, and early on they were
discovered to be elevated in the plasma of patients with
endocrine tumors. Plasma chromogranin A (CgA) has been
reported to be a prognostic biomarker in GEP-NETs,
correlating with hepatic tumor burden and with shorter
survival. In the setting of radically operated midgut
carcinoids, elevation of CgA has been reported to be both
a diagnostic marker and an early marker of recurrent
disease. A decrease in CgA levels has been used as a marker
of response to treatment in clinical trials, for which
biochemical response usually is defined as a $50%
reduction of CgA (31–33). The combination of CgA levels
and levels of N-terminal pro-brain natriuretic peptide (Nt-
proBNP) correlate significantly with carcinoid heart disease
(i.e., right-sided heart failure due to tricuspid regurgitation
and/or pulmonic stenosis because of valve fibrosis (prob-
ably) caused by elevated circulating serotonin) (34).
There are, however, several limitations to the use of CgA
as a biomarker in GEP-NETs. Treatment with proton-pump
inhibitors can cause a secondary increase in CgA as a result
of the increased gastrin production. Chronic atrophic
gastritis may also cause elevated CgA. Impaired renal
function may cause accumulation of the peptide, which also
results in falsely elevated levels. Many patients with midgut
carcinoids are initially misdiagnosed with irritable bowel
syndrome, sometimes several years before the correct
diagnosis is made (35). There have been reports of elevated
CgA in irritable bowel syndrome and in inflammatory
bowel disease. CgA is thus not of value as a screening test in
the evaluation of unclear diarrhea.
There has been impressive progress in the field of
biomarkers as well as molecular imaging. However, we
still need more sensitive markers for early detection and
follow-up. Furthermore, new markers delineating sensitiv-
ity to various therapies are warranted. Molecular imaging is
in its early stages and has the potential to be a significant
tool in the management of patients with NETs.
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